Effect of Nonalcoholic Fatty Liver Disease on the Development of Type 2 Diabetes in Nonobese, Nondiabetic Korean Men
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: We have a limited understanding of the effect of nonalcoholic fatty liver disease (NAFLD) on the development of type 2 diabetes. Methods: The study subjects included male who had received biennial medical check-ups between 2005 and 2009 and who had been diagnosed with fatty liver disease. The subjects with sustained NAFLD (FL, n=107) and sustained non-NAFLD (NFL, n=1,054) were followed to determine the development of type 2 diabetes. Results: In the FL group, there were more subjects with impaired fasting glucose (IFG), type 2 diabetes and high HOMA-IR than there were in the NFL group during the 5-year follow-up period (32.7 vs. 17.6%, 1.9 vs. 0.3%, 17.9 vs. 5.2% respectively, p<0.05). The FL group showed a higher risk than NFL group for abnormal glucose metabolism as determined using IFG (odds ratio [OR], 2.13; confidence interval [CI], 1.36 to 3.35), type 2 diabetes (OR, 7.63; 95% CI, 1.03 to 56.79) and high HOMA-IR (OR, 3.25; 95% CI, 1.79 to 5.91) and metabolic parameters such as body mass index (OR, 3.35; 95% CI, 1.87 to 6.02), triglyceride (OR, 3.05; 95% CI, 1.92 to 4.86) and fasting blood sugar (OR, 2.18; 95% CI, 1.39 to 3.41). Conclusions: Sustained NAFLD appears to be associated with an increased risk for the development of type 2 diabetes and deterioration of metabolic parameters in non-obese, non-diabetic Korean men.
Abstract
Background/Aims: We have a limited understanding of the effect of nonalcoholic fatty liver disease (NAFLD) on the development of type 2 diabetes. Methods: The study subjects included male who had received biennial medical check-ups between 2005 and 2009 and who had been diagnosed with fatty liver disease. The subjects with sustained NAFLD (FL, n=107) and sustained non-NAFLD (NFL, n=1,054) were followed to determine the development of type 2 diabetes. Results: In the FL group, there were more subjects with impaired fasting glucose (IFG), type 2 diabetes and high HOMA-IR than there were in the NFL group during the 5-year follow-up period (32.7 vs. 17.6%, 1.9 vs. 0.3%, 17.9 vs. 5.2% respectively, p<0.05). The FL group showed a higher risk than NFL group for abnormal glucose metabolism as determined using IFG (odds ratio [OR], 2.13; confidence interval [CI], 1.36 to 3.35), type 2 diabetes (OR, 7.63; 95% CI, 1.03 to 56.79) and high HOMA-IR (OR, 3.25; 95% CI, 1.79 to 5.91) and metabolic parameters such as body mass index (OR, 3.35; 95% CI, 1.87 to 6.02), triglyceride (OR, 3.05; 95% CI, 1.92 to 4.86) and fasting blood sugar (OR, 2.18; 95% CI, 1.39 to 3.41). Conclusions: Sustained NAFLD appears to be associated with an increased risk for the development of type 2 diabetes and deterioration of metabolic parameters in non-obese, non-diabetic Korean men.
참고문헌 (31)
- Brunt EM, "Nonalcoholic steatohepatitis: definition and pathology", Semin Liver Dis, 21, pp.3~16 (2001)
- 박승하, "Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 21(1 Pt 1), pp.138~143, BLACKWELL PUBLISHING
- Farrell GC, "Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?", J Gastroenterol Hepatol, 18, pp.124~138 (2003)
- Choudhury J, "Clinical aspects of fatty liver disease", Semin Liver Dis, 24, pp.349~362 (2004)
- Eckel RH, "The metabolic syndrome", Lancet, 365, pp.1415~1428 (2005)
- Fan JG, "Prevalence of and risk factors for fatty liver in a general population of Shanghai, China", J Hepatol, 43, pp.508~514 (2005)
- Marchesini G, "Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome", Hepatology, 37, pp.917~923 (2003)
- Marchesini G, "Nonalcoholic fatty liver disease: a feature of the metabolic syndrome", Diabetes, 50, pp.1844~1850 (2001)
- Bedogni G, "Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study", Hepatology, 42, pp.44~52 (2005)
- Knobler H, "Fatty liver: an additional and treatable feature of the insulin resistance syndrome", QJM, 92, pp.73~79 (1999)
- Seppälä-Lindroos A, "Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men", J Clin Endocrinol Metab, 87, pp.3023~3028 (2002)
- Day CP, "Non-alcoholic steatohepatitis: definitions and pathogenesis", J Gastroenterol Hepatol, 17(Suppl 3), pp.S377~S384 (2002)
- Exert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, "Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)", JAMA, 285, pp.2486~2497 (2001)
- American Diabetes Association, "Standards of medical care in diabetes: 2010", Diabetes Care, 33(Suppl 1), pp.S11~S61 (2010)
- Saadeh S, "The utility of radiological imaging in nonalcoholic fatty liver disease", Gastroenterology, 123, pp.745~750 (2002)
- Fan JG, "Fatty liver and the metabolic syndrome among Shanghai adults", J Gastroenterol Hepatol, 20, pp.1825~1832 (2005)
- Friis-Liby I, "High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease", Scand J Gastroenterol, 39, pp.864~869 (2004)
- Fan JG, "A study of the changes of hepatic gene expression in the process of nonalcoholic fatty liver disease development using U230A oligonucleotide microarray", Zhonghua Gan Zang Bing Za Zhi, 13, pp.597~601 (2005)
- Ekstedt M, "Survival and causes of death in patients with elevated liver enzymes associated with non-alcoholic fatty liver disease (NAFLD)", J Hepatol, 44(Suppl 2), pp.S40~S41 (2006)
- Singh SP, "Non-alcoholic fatty liver disease: the unfolding monster?", J Gastroenterol Hepatol, 21(1 Pt 2), pp.199~201 (2006)
- Hamaguchi M, "The metabolic syndrome as a predictor of nonalcoholic fatty liver disease", Ann Intern Med, 143, pp.722~728 (2005)
- Paradis V, "High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis", Hepatology, 34, pp.738~744 (2001)
- Ozcan U, "Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes", Science, 306, pp.457~461 (2004)
- Svegliati-Baroni G, "Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways", Hepatology, 29, pp.1743~1751 (1999)
- Sanyal AJ, "Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities", Gastroenterology, 120, pp.1183~1192 (2001)
- Marchesini G, "Association of nonalcoholic fatty liver disease with insulin resistance", Am J Med, 107, pp.450~455 (1999)
- 배지철, "Impact of Nonalcoholic Fatty Liver Disease on Insulin Resistance in Relation to HbA1c Levels in Nondiabetic Subjects", AMERICAN JOURNAL OF GASTROENTEROLOGY, 105, pp.2389~2395, Nature publish group
- Stefan N, "Causes and metabolic consequences of fatty liver", Endocr Rev, 29, pp.939~960 (2008)
- Fan JG, "Effects of nonalcoholic fatty liver disease on the development of metabolic disorders", J Gastroenterol Hepatol, 22, pp.1086~1091 (2007)
- Shibata M, "Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men", Diabetes Care, 30, pp.2940~2944 (2007)
- Kim HJ, "Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults", Arch Intern Med, 164, pp.2169~2175 (2004)